EBITDA Margin % is calculated as EBITDA divided by its Revenue. HCW Biologics's EBITDA for the
three
months ended in Mar. 2026 was $4.07 Mil. HCW Biologics's Revenue for the
three
months ended in Mar. 2026 was $6.54 Mil. Therefore, HCW Biologics's EBITDA margin for the quarter that ended in Mar. 2026 was 62.17%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
HCW Biologics EBITDA Margin % Related Terms
HCW Biologics EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for HCW Biologics's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCWB vs MTVA, INTI, HOOK: EBITDA Margin % Comparison
For the Biotechnology subindustry, HCW Biologics's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
HCW Biologics EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, HCW Biologics's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where HCW Biologics's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HCW Biologics (HCWB) has a EBITDA Margin % of 62.17% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HCW Biologics and its competitors. According to the industry distribution chart, HCW Biologics ranks #333 out of 945 companies in the Biotechnology industry, placing it in the top 35.2%.
Is HCW Biologics' EBITDA Margin % too high?
HCW Biologics' current EBITDA Margin % is 62.17%. Based on the distribution chart, HCW Biologics ranks #333 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, HCW Biologics has a GF Score™ of 39/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does HCW Biologics' EBITDA Margin % compare to MTVA and INTI?
According to the Biotechnology industry distribution chart, HCW Biologics ranks #333 out of 945 companies for EBITDA Margin %. This puts HCW Biologics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on HCW Biologics and its competitors. HCW Biologics's current EBITDA Margin % is 62.17%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HCW Biologics stock overvalued right now?
Based on GuruFocus' analysis, HCW Biologics (HCWB) is currently considered Possible Value Trap. The stock's GF Value™ is $7.29, compared to a current price of $1.15 — trading 84.3% below its estimated fair value. The current EBITDA Margin % is 62.17%. HCW Biologics' overall GF Score™ is 39/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For HCW Biologics (HCWB), the current EBITDA Margin % is 62.17% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is HCW Biologics (HCWB) Overvalued in 2026?
Based on GuruFocus' analysis, HCW Biologics stock appears to be undervalued.
The current stock price of $1.15 is trading 84.3% below its estimated GF Value™ of $7.29.
GuruFocus considers HCW Biologics to be Possible Value Trap.
Key valuation signals for HCWB:
EBITDA Margin %: 62.17%
GF Value™: $7.29 vs. price of $1.15 (84.3% below fair value)
No single metric tells the full story. See the HCWB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
HCW Biologics Inc is a clinical-stage biopharmaceutical company developing transformative fusion immunotherapeutics to support or treat diseases promoted by chronic inflammation. It has created novel compounds that represent a new class of drugs that it believes has the potential to fundamentally change the treatment of autoimmune disorders and other proinflammatory diseases, cancer and senescence-associated dysplasia. The company has developed two proprietary drug discovery and development platforms which it uses to create novel fusion immunotherapeutics: The TOBI (Tissue factOr-Based fusIon) platform, and The T-cell Receptor Beta Chain constant region (TRBC) platform. It operates and manages its business as one reportable segment.
39GF Score
Get the complete analysis for HCWB
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HCWB has been successfully added to your 
